1-[3-甲基-4-(甲基氨基)苯基]乙酮 | 265107-37-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-[3-甲基-4-(甲基氨基)苯基]乙酮
• 英文名称: 1-(3-methyl-4-methylaminophenyl)ethanone
• 英文别名: 1-[3-Methyl-4-(methylamino)phenyl]ethanone
• CAS: 265107-37-7
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: CBFKTHWERVXZBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[3-甲基-4-(甲基氨基)苯基]乙酮 在 乙酸铵 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 N-{4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methylphenyl}-N-methylformamide
  参考文献：
  名称：

  5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

  摘要：

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.023
• 作为产物：
  描述：

  2-氟甲苯 在 三氯化铝 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 反应 42.0h， 生成 1-[3-甲基-4-(甲基氨基)苯基]乙酮
  参考文献：
  名称：

  5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

  摘要：

  4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.03.023

文献信息

• FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES
  申请人：Galapagos N.V.

  公开号：EP3782997A1

  公开（公告）日：2021-02-24

  The present invention discloses compounds according to Formula I: Wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, pain, and/or abnormal angiogenesis associated diseases by administering the compounds of the invention.

  本发明公开了根据式I的化合物：其中A、B、R1、R2和Cy如本文所定义。本发明涉及抑制自体脂肪酶（NPP2或ENPP2）的化合物，其生产方法，包含其的药物组合物，以及使用该化合物进行预防和/或治疗纤维化疾病、增生性疾病、炎症性疾病、自身免疫疾病、呼吸系统疾病、心血管疾病、神经退行性疾病、皮肤疾病、疼痛和/或异常血管生成相关疾病的方法。
• SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS
  申请人：Heinrich Heine Universität Düsseldorf

  公开号：EP2797417B1

  公开（公告）日：2019-07-31
• SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES
  申请人：Heinrich Heine Universitat Dusseldorf

  公开号：US20150216167A1

  公开（公告）日：2015-08-06

  The present invention relates to the use of a compound, a salt or solvate thereof as C4 plant selective herbicide wherein said compound comprises a cyclic alkyl, aryl, heterocycloalkyl or heteroaryl group, and wherein said compound further comprises a) at least a functional group Z being —C(═Y z )R 1 , wherein Y z is selected from the group consisting of O, NH and S, preferably wherein Y z is O, and wherein R 1 is selected from the group consisting of H, OH and N(R 2 R 3 ), —O(R 2 ) and —S(R 2 ), wherein R 2 and R 3 , are independently of each other, selected from the group consisting of H, alkyl, cycolalkyl, aryl and heteroaryl and a functional group Q which is —C(═Y Q )R 4 , wherein Y Q is selected from the group consisting of O, NH and S, preferably wherein Y Q is O, and wherein R 4 is selected from the group consisting of H, OH and NR 4# R 5# , OR 4# , SR 4# wherein R 4# and R 5# , are independently of each other, selected from the group consisting of H, alkyl, cycloalkyl, aryl and heteroaryl, or b) at least one electron donating group selected from the group consisting of OH, —SH, —O—R p , S—R p —NR p R q and O—C(═Y p )R r , wherein R p and R q are, independently of each other, selected from the group consisting of H, alkyl, cycloalkyl and heteroaryl, and wherein R r is —OH, —NH 2 , —NH-Alkyl, —O-Alkyl or —NH-Alkyl, and wherein Y p is selected from the group consisting of —S—, —O—, —NH, said compound being capable of binding to the malate binding site comprised by a phosphoenolpyruvate carboxylase from a C4 plant, thereby inhibiting said phosphoenolpyruvate carboxylase, and wherein the cyclic alkyl, aryl, heterocycloalkyl or heteroaryl group inhibits binding to the malate binding site of a phosphoenolpyruvate carboxylase from a C3 plant.
• US9365612B2
  申请人：——

  公开号：US9365612B2

  公开（公告）日：2016-06-14
• [EN] SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS<br/>[FR] INHIBITION SÉLECTIVE DE PHOSPHOÉNOLPYRUVATE CARBOXYLASES DE PLANTES C4
  申请人：UNIV DUESSELDORF H HEINE

  公开号：WO2013093007A1

  公开（公告）日：2013-06-27

  The present invention relates to the use of a compound, a salt or solvate thereof as C4 plant selective herbicide wherein said compound comprises a cyclic alkyl, aryl, heterocycloalkyl or heteroaryl group, and wherein said compound further comprises a) at least a functional group Z being -C(=Yz)R1, wherein Yz is selected from the group consisting of O, NH and S, preferably wherein Yz is O, and wherein R1 is selected from the group consisting of H, OH and N(R2R3), -O(R2) and -S(R2), wherein R2 and R3, are independently of each other, selected from the group consisting of H, Alkyl, cycolalkyl, aryl and heteroaryl and a functional group Q which is -C(=YQ)R4, wherein YQ is selected from the group consisting of O, NH and S, preferably wherein YQ is O, and wherein R4 is selected from the group consisting of H, OH and NR4#R5#, OR4#, SR4# wherein R4# and R5#, are independently of each other, selected from the group consisting of H, alkyl, cycloalkyl, aryl and heteroaryl, or b) at least one electron donating group selected from the group consisting of OH, -SH, -O-Rp, -S-Rp -NRpRq and O-C(=Yp)Rr, wherein Rp and Rq are, independently of each other, selected from the group consisting of H, alkyl, cycloalkyl and heteroaryl, and wherein Rr is -OH, -NH2, -NH-Alkyl, -O-Alkyl or -NH-Alkyl, and wherein Yp is selected from the group consisting of -S-, -O-, -NH, said compound being capable of binding to the malate binding site comprised by a phosphoenolpyruvate carboxylase from a C4 plant, thereby inhibiting said phosphoenolpyruvate carboxylase, and wherein the cyclic alkyl, aryl, heterocycloalkyl or heteroaryl group inhibits binding to the malate binding site of a phosphoenolpyruvate carboxylase from a C3 plant.